Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourStrong Bearish
15 minBearish
5 minStrong Bearish
Daily trend turns up above $21.76
Key levels
Resistance$20.51
Resistance$19.42
Support$18.66
Support$17.93
Latest news & SEC filings
ProductInnoviva says NUZOLVENCE now commercially available in the U.S.
AnalystOppenheimer Changes Its Innoviva Price Target
AnalystOppenheimer keeps Outperform rating on Innoviva, cuts price target to $34
EarningsInnoviva Posts Q3 2026 Results
All INVA news →Innoviva is a biopharmaceutical company that earns payments from GlaxoSmithKline based on sales of two once-daily inhaled lung medicines used for asthma and COPD. It also operates a hospital-focused business selling five approved drugs that address septic shock, hard-to-treat bacterial pneumonia, abdominal infections, bloodstream infections, and gonorrhea. The company backs other medical ventures, including a stake in a phage therapy developer. Its medicines are cleared for sale in the U.S., Europe, China, and elsewhere.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
SEPT Low Target
$29.75
SEPT Mid Target
$35.00
SEPT High Target
$40.25
Analyst Consensus
$35.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for INVA.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$35.88
62
Moat Score
NARROW
4/9
Piotroski Score
N/A
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Basso Stephen | officer | Sale | 559 | $12K | May 20, 2026 |
| Raifeld Pavel | director officer | Sale | 1,130 | $25K | May 20, 2026 |
| Zhen Marianne | officer | Sale | 1,127 | $25K | May 20, 2026 |
| Linden Josephine | director | Buy | 5,733 | - | May 18, 2026 |
| Linden Josephine | director | Buy | 9,461 | - | May 18, 2026 |
| Basso Stephen | officer | Buy | 1,123 | - | May 15, 2026 |
| Raifeld Pavel | director officer | Buy | 1,123 | - | May 15, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
14.7%
3yr Revenue CAGR
7.5%
EPS Growth YoY
816.67%
FCF Growth YoY
3.9%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for INVA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:08:28 | $19.02 | 1,359 | $$26K | SELL |
| 17:20:48 | $19.06 | 6,908 | $$132K | BUY |
| 16:01:25 | $19.09 | 1,200 | $$23K | SELL |
| 14:43:16 | $18.98 | 4,200 | $$80K | SELL |
| 21:00:19 | $18.97 | 2,400 | $$46K | SELL |
5 dark pool trades shown · $$306K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Innoviva, Inc. (INVA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Innoviva, Inc. (INVA) is at $19.03, up 0.32% (+$0.06) at the Nov 13, 2026 close.
Latest INVA news — Nov 5, 2026: Innoviva says NUZOLVENCE now commercially available in the U.S. · Nov 5, 2026: Oppenheimer Changes Its Innoviva Price Target
The average analyst price target for INVA is $35.00, ranging from $34 to $42, based on 3 analysts.
Analyst ratings for INVA: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
INVA last reported on Aug 5, 2026: EPS $1.14 vs $0.44 expected — a beat of 161.5%.
INVA trades at a P/E of 6.5.
INVA does not currently pay a dividend.
Support: $18.66, $17.93, $17.22. Resistance: $19.42, $20.51, $21.65.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 5, 2026: Innoviva says NUZOLVENCE now commercially available in the U.S. · Nov 5, 2026: Oppenheimer Changes Its Innoviva Price Target · Nov 5, 2026: Oppenheimer keeps Outperform rating on Innoviva, cuts price target to $34